TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32758087

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) - 60 J per site, 6 sites per limb, total dose = 360 J
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14
Study: 34197956

Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mL (0.75%) infiltrated into the retroperitoneal space overlying the superior hypogastric plexus
Number of subjects: 50

Group type: COMPARATOR
Intervention: No block given at the completion of surgery
Number of subjects: 50
Study: 33301153

Group type: EXPERIMENTAL
Intervention: Weighted kappa used for multilevel outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cohen’s kappa
Number of subjects: 0
Study: 34458718

Group type: EXPERIMENTAL
Intervention: Heparinoid-containing product (HCP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-skin care (Control)
Number of subjects: 20
Study: 35449996

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir (S.L. group)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Oseltamivir/Hydroxychloroquine/Azithromycin (OCH group)
Number of subjects: 250
Study: 33829225

Group type: EXPERIMENTAL
Intervention: Combination of subsidies on healthy products and taxes on unhealthy products in the nudging and price salience condition
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 318
Study: 35562520

Group type: EXPERIMENTAL
Intervention: Stress-related humor
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Stress-unrelated humor
Number of subjects: 94

Group type: COMPARATOR
Intervention: Non-humorous regulation
Number of subjects: 94
Study: 32722931

Group type: EXPERIMENTAL
Intervention: Fundus Automated Perimetry (FAP)
Number of subjects: 60
Study: 36495775

Group type: EXPERIMENTAL
Intervention: Protective ventilation (PV): tidal volume = 6 ml/kg of predicted body weight, PEEP = 10 cmH2O, recruitment maneuvers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard ventilation (SV): tidal volume = 10 ml/kg of predicted body weight, PEEP = 5 cmH2O
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Protective ventilation (PV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard ventilation (SV)
Number of subjects: 60
Study: 33712249

Group type: EXPERIMENTAL
Intervention: Epidural Volume Extension (EVE) with 5mg intrathecal bupivacaine
Number of subjects: 84

Group type: COMPARATOR
Intervention: No EVE with 5mg intrathecal bupivacaine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Epidural Volume Extension (EVE) with 8mg intrathecal bupivacaine
Number of subjects: 84

Group type: COMPARATOR
Intervention: No EVE with 8mg intrathecal bupivacaine
Number of subjects: 84
Study: 35631280

Group type: EXPERIMENTAL
Intervention: DHA+EPA supplementation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (high‐oleic safflower oil)
Number of subjects: 29
Study: 35742365

Group type: EXPERIMENTAL
Intervention: EG1 (psychomotor intervention program)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: EG2 (combined program: psychomotor intervention + whole-body vibration)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 33453747

Group type: EXPERIMENTAL
Intervention: Child and Adolescent Behavior Inventory
Number of subjects: 2142
Study: 34958394

Group type: EXPERIMENTAL
Intervention: Sof-Lex discs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: nano-hydroxyapatite serum
Number of subjects: 20

Group type: COMPARATOR
Intervention: carbide bur alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: combination of carbide burs and Sof-Lex discs
Number of subjects: 20
Study: 32051007

Group type: EXPERIMENTAL
Intervention: Early oral switch therapy for low-risk Staphylococcus aureus infection
Number of subjects: 215

Group type: COMPARATOR
Intervention: Standard treatment (not explicitly mentioned in the abstract)
Number of subjects: 215
Study: 33938307

Group type: EXPERIMENTAL
Intervention: PGX-guided treatment
Number of subjects: 182

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 182
Study: 32941700

Group type: EXPERIMENTAL
Intervention: Thiazide diuretic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blocker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker
Number of subjects: 0
Study: 97434094

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study: 35576956

Group type: EXPERIMENTAL
Intervention: Adebrelimab plus chemotherapy (carboplatin and etoposide)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (carboplatin and etoposide)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Adebrelimab plus chemotherapy
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 462
Study: 33472641

Group type: EXPERIMENTAL
Intervention: Hypertonic sodium infusion
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High sodium diet
Number of subjects: 27
Study: 36001620

Group type: EXPERIMENTAL
Intervention: Application-supported pathway for the emergency department (ED) care for atraumatic abdominal pain patients.
Number of subjects: 2000
Study: 34992516

Group type: EXPERIMENTAL
Intervention: High-fat meal (En% fat, carbohydrates, protein: 52.3, 39.2, 8.0)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (En% fat, carbohydrates, protein: 9.6, 81.5, 8.6)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-protein meal (En% fat, carbohydrates, protein: 10.6, 51.5, 36.9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Plasma measurements (control group for comparison)
Number of subjects: 18
Study: 32985780

Group type: EXPERIMENTAL
Intervention: Ultraslow full-power shock wave lithotripsy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Slow-rate, power-ramping shock wave lithotripsy
Number of subjects: 101
Study: 33010371

Group type: EXPERIMENTAL
Intervention: i-gel supraglottic airway device (SGA)
Number of subjects: 9296

Group type: COMPARATOR
Intervention: Tracheal intubation (TI)
Number of subjects: 9296
Study: 35533205

Group type: EXPERIMENTAL
Intervention: RefineNet
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: FCN
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: U-Net
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: CE-Net
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: UNet3D
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: ResUNet3D
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: RefineNetPlus3D
Number of subjects: 313
Study: 32554291

Group type: EXPERIMENTAL
Intervention: CLIP intervention (community engagement, CHW provided mHealth-guided clinical assessment, initial treatment, and referral)
Number of subjects: 14783

Group type: EXPERIMENTAL
Intervention: CLIP intervention with ≥8 contacts
Number of subjects: 14783

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 14783
Study: 35731889

Group type: EXPERIMENTAL
Intervention: 20 mg of suvorexant
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 40 mg of suvorexant
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 32207140

Group type: EXPERIMENTAL
Intervention: Medical expulsive therapy (MET) with 0.4 mg daily tamsulosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 35829772

Group type: EXPERIMENTAL
Intervention: Chitosan gel + 0.1 mg/mL CaneCPI-5 (Cg + Cane)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chitosan gel + 12,300 ppm NaF (Cg + NaF)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chitosan gel (Cg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No treatment (Nt)
Number of subjects: 16
Study: 34753906

Group type: EXPERIMENTAL
Intervention: MPG-peptide
Number of subjects: 0
Study: 32196621

Group type: EXPERIMENTAL
Intervention: Myo-inositol (MI) treatment
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 86
Study: 35107029

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) - 5 sets of 10 repetitions at 75% of one-repetition maximum
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham Control (seated rest)
Number of subjects: 39
Study: 33753043

Group type: EXPERIMENTAL
Intervention: dd‐MVAC (dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 97

Group type: COMPARATOR
Intervention: dd‐MVAC+Pmab (dd‐MVAC with panitumumab)
Number of subjects: 97

Group type: COMPARATOR
Intervention: dd‐MVAC and dd‐MVAC+Pmab
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: dd‐MVAC+Pmab
Number of subjects: 97
Study: 36054143

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (800 mg/day for 4 days)
Number of subjects: 38
Study: 33431282

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Myofascial Release (MR)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham Dry Needling (sham DN)
Number of subjects: 44
Study: 32022890

Group type: EXPERIMENTAL
Intervention: Mind-body intervention (five 90-minute sessions)
Number of subjects: 20
Study: 35578103

Group type: EXPERIMENTAL
Intervention: Participatory art-based activity (2 hours weekly for 12 weeks)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (no art-based intervention)
Number of subjects: 228
Study: 34753480

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg orally once daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 35762612

Group type: EXPERIMENTAL
Intervention: Prophylactic retrorectus mesh reinforcement (MESH group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Primary closure of midline laparotomy (NOMESH group)
Number of subjects: 120
Study: 33399309

Group type: EXPERIMENTAL
Intervention: Second-line HIV therapy
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: TB co-infection
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Low CD4+ T-cell count
Number of subjects: 355
Study: 35573994

Group type: EXPERIMENTAL
Intervention: Daily somatropin 0.05 mg/kg/day
Number of subjects: 481

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 481
Study: 34258380

Group type: EXPERIMENTAL
Intervention: Dual antithrombotic therapy (DAT) with apixaban plus clopidogrel
Number of subjects: 400

Group type: COMPARATOR
Intervention: Triple antithrombotic therapy (TAT) with vitamin-K-antagonist (VKA) plus clopidogrel and acetylsalicylic acid
Number of subjects: 400
Study: 32007604

Group type: EXPERIMENTAL
Intervention: Risperidone (RISP)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Divalproex Sodium (DVPX)
Number of subjects: 175
Study: 32670199

Group type: EXPERIMENTAL
Intervention: Jinlida granules, 9 g/time, three times daily for 2-4 years, in addition to lifestyle intervention
Number of subjects: 880

Group type: COMPARATOR
Intervention: Placebo, orally, 9 g/time, three times daily for 2-4 years, in addition to lifestyle intervention
Number of subjects: 880
Study: 34169656

Group type: EXPERIMENTAL
Intervention: Fat grafting with PRP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fat grafting
Number of subjects: 18

Group type: COMPARATOR
Intervention: Routine podiatry care
Number of subjects: 18
Study: 34905220

Group type: EXPERIMENTAL
Intervention: Single dose of primaquine (0.25 mg base/kg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Single dose of primaquine (0.0625 to 0.5 mg base/kg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 34651260

Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of 0.5 ml PRP 48 h before embryo transfer
Number of subjects: 393

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 393
Study: 34036409

Group type: EXPERIMENTAL
Intervention: 4DryField® PH
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 50
Study: 32382866

Group type: EXPERIMENTAL
Intervention: Surgical management offered by 13% (n=3) of surgeons in all scenarios.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Surgical management offered by 43% (n=10) of surgeons only in cases presenting with symptoms.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Variable surgical approach indicated by 43% (n=10) of surgeons.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: No surgery for incontinence indicated by 9% (n=2) of participants.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Prophylactic surgery favored by 43% of participants for asymptomatic sacral LMM.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Conservative management preferred by 57% of participants for asymptomatic sacral LMM.
Number of subjects: 23
Study: 35504639

Group type: EXPERIMENTAL
Intervention: Sacral fracture fixation (cement augmentation±screw fixation) within 7 days of randomisation.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Usual care consisting of analgesia, and regular input from the medical and therapy team.
Number of subjects: 13
Study: 32216556

Group type: EXPERIMENTAL
Intervention: Assistive Technology (AT) awareness and need assessment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tactile/sound-based ATs
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Vision-based ATs
Number of subjects: 250
Study: 35477489

Group type: EXPERIMENTAL
Intervention: 16-week Home-Based Physical Activity Intervention
Number of subjects: 312

Group type: COMPARATOR
Intervention: Educational Attention control group
Number of subjects: 312
Study: 34542671

Group type: EXPERIMENTAL
Intervention: CE (cross-education): strength training of the non-operative limb
Number of subjects: 44

Group type: COMPARATOR
Intervention: CON (control): sham exercise of upper limb stretching
Number of subjects: 44
Study: 34920733

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 62

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 62
Study: 32854533

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Stress Management Therapy (SMT) for 12 weeks
Number of subjects: 87
Study: 34776442

Group type: EXPERIMENTAL
Intervention: EMMA app with smart home prompting
Number of subjects: 32

Group type: COMPARATOR
Intervention: EMMA app only
Number of subjects: 32
Study: 33886693

Group type: EXPERIMENTAL
Intervention: Adapted-Family DSME
Number of subjects: 221

Group type: COMPARATOR
Intervention: Standard DSME
Number of subjects: 221
Study: 33367600

Group type: EXPERIMENTAL
Intervention: Craniofacial morphology in UCLP group
Number of subjects: 429
Study: 33871648

Group type: EXPERIMENTAL
Intervention: Capsaicin 179 mg cutaneous patch
Number of subjects: 619
Study: 36070664

Group type: EXPERIMENTAL
Intervention: Health coach and smartphone application (app) driven intervention
Number of subjects: 256

Group type: COMPARATOR
Intervention: Attention-control condition
Number of subjects: 256
Study: 33714169

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture therapy for 2 hours combined with rehabilitation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rehabilitation training alone
Number of subjects: 0
Study: 35427190

Group type: EXPERIMENTAL
Intervention: TreoMel-HDT
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control
Number of subjects: 109
Study: 33795189

Group type: EXPERIMENTAL
Intervention: Bonded spurs associated with posterior build-ups (SBU)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Bonded spurs alone (S)
Number of subjects: 49
Study: 35766991

Group type: EXPERIMENTAL
Intervention: One-on-one 30- to 45-minute psychosocial counseling session with a psychosexual counselor plus written educational materials
Number of subjects: 31

Group type: COMPARATOR
Intervention: Written materials alone
Number of subjects: 31
Study: 33370833

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 210

Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Natural killer cell activity
Number of subjects: 210
Study: 32817142

Group type: EXPERIMENTAL
Intervention: 99mTc-ADAPT6 (500 μg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 99mTc-ADAPT6 (250 μg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 99mTc-ADAPT6 (1,000 μg)
Number of subjects: 29
Study: 35834226

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX (8 cycles: oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, infusional fluorouracil 2400 mg/m2 over 46 hours, every 2 weeks)
Number of subjects: 126

Group type: COMPARATOR
Intervention: mFOLFIRINOX followed by hypofractionated radiotherapy (7 cycles of mFOLFIRINOX followed by 33-40 Gy in 5 fractions or 25 Gy in 5 fractions)
Number of subjects: 126
Study: 32056811

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 189

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 189
Study: 35616245

Group type: EXPERIMENTAL
Intervention: Jump training (16-week program)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (regular soccer training)
Number of subjects: 23
Study: 33440243

Group type: EXPERIMENTAL
Intervention: RC18 (a novel recombinant fusion protein targeting BLyS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: RC18
Number of subjects: 23
Study: 32146440

Group type: EXPERIMENTAL
Intervention: Circuit Resistance Training (CRT) for 8 weeks, 3 times a week
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Circuit Resistance Training (CRT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 36217555

Group type: EXPERIMENTAL
Intervention: Cold Atmospheric Plasma (CAP) treatment biweekly for five sessions
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patient satisfaction ratings
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Safety assessment using VAS
Number of subjects: 23
Study: 33495378

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to T2D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher HbA1c levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to insulin resistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to β‐cell dysfunction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid atherosclerotic plaque
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fractional anisotropy (white matter disease marker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markers of brain atrophy
Number of subjects: 0
Study: 34044738

Group type: EXPERIMENTAL
Intervention: Breathing exercise program performed twice per day for one month
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Breathing exercise program
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (incentive spirometer)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 33638661

Group type: EXPERIMENTAL
Intervention: Amyloid-PET (first exam)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Tau-PET (first exam)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Amyloid-PET (second exam)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Tau-PET (second exam)
Number of subjects: 136
Study: 32758761

Group type: EXPERIMENTAL
Intervention: Chewing with initial breakage (N=1)
Number of subjects: 31
Study: 36202725

Group type: EXPERIMENTAL
Intervention: TAHSNp Health Professions Innovation Fellowship program
Number of subjects: 25
Study: 33946717

Group type: EXPERIMENTAL
Intervention: Exercise referral schemes and self‐management strategies
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group participants
Number of subjects: 83
Study: 35078923

Group type: EXPERIMENTAL
Intervention: Induction chemoimmunotherapy followed by chemotherapy-free radioimmunotherapy (RIT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: RIT cohort (n=60)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: RIT for HPV-positive oropharyngeal cancers
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: RIT for HPV-negative oropharyngeal cancers and other locations
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Entire study cohort (n=79)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Toxicity grade 3-4
Number of subjects: 79
Study: 33787533

Group type: EXPERIMENTAL
Intervention: XGBoost model for early mortality prediction
Number of subjects: 938

Group type: COMPARATOR
Intervention: Logistic regression model
Number of subjects: 938

Group type: COMPARATOR
Intervention: Support vector machine model
Number of subjects: 938

Group type: COMPARATOR
Intervention: Random forest model
Number of subjects: 938

Group type: COMPARATOR
Intervention: Naive Bayesian model
Number of subjects: 938

Group type: COMPARATOR
Intervention: Sequential Organ Failure Assessment score
Number of subjects: 938

Group type: COMPARATOR
Intervention: Acute Physiology Score III
Number of subjects: 938
Study: 32392996

Group type: EXPERIMENTAL
Intervention: Low-Intensity Pulsed Ultrasound (LIPUS) applied 3 times per week
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-Intensity Pulsed Ultrasound (LIPUS) applied 2 times per week
Number of subjects: 40
Study: 35191065

Group type: EXPERIMENTAL
Intervention: Soft-type block bone substitute (synthetic biphasic calcium phosphate + collagen)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Particulate bone substitute (biphasic calcium phosphate)
Number of subjects: 40
Study: 33227223

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine hydrochloride film
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34882063

Group type: EXPERIMENTAL
Intervention: Irregular cycle variability (>6 days)
Number of subjects: 3473

Group type: COMPARATOR
Intervention: Regular cycle variability (≤6 days)
Number of subjects: 3473
Study: 32776464

Group type: EXPERIMENTAL
Intervention: L-citrulline (CIT) supplementation (6g/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33109739

Group type: EXPERIMENTAL
Intervention: 5 years of extended letrozole
Number of subjects: 908

Group type: COMPARATOR
Intervention: 2.5 years of extended letrozole
Number of subjects: 908
Study: 32348442

Group type: EXPERIMENTAL
Intervention: Distal jet group (DJG, n=25)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Jones jig group (JJG, n=30)
Number of subjects: 71

Group type: COMPARATOR
Intervention: First Class group (FCG, n=16)
Number of subjects: 71
Study: 35616421

Group type: EXPERIMENTAL
Intervention: 30 min group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 60 min group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 90 min group
Number of subjects: 90